INGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Inogen Inc (INGN) is not a strong buy for a beginner, long-term investor at this time. While there are some positive developments such as the share repurchase program and international growth, the company's financial performance shows declining profitability and margins. Additionally, there are no strong trading signals or significant insider or hedge fund activity to support an immediate buy decision.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral, and moving averages are converging, which does not provide a clear trend. The stock is trading near its resistance level (R1: 6.317), suggesting limited short-term upside potential.
The company reported 4% YoY revenue growth for the full year
International revenue grew 15% YoY in Q4
The company initiated a $30 million share repurchase program, signaling confidence from the Board.
New product developments such as Simeox and the nearing completion of a clinical study in China could drive future growth.
Net income dropped significantly (-26.96% YoY) in Q4 2025, and EPS declined by -36.59% YoY.
Gross margin decreased by -4.85% YoY, reflecting potential cost pressures.
The stock experienced a post-market decline of -2.17%, indicating some bearish sentiment.
In Q4 2025, revenue grew 2.05% YoY to $81.72 million. However, net income dropped to -$7.13 million (-26.96% YoY), and EPS fell to -$0.26 (-36.59% YoY). Gross margin also declined to 43.12% (-4.85% YoY), highlighting profitability challenges.
No recent data on analyst ratings or price target changes is available.
